$FHTX
Foghorn Therapeutics Inc. Stock $fhtx

$fhtx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000162828022005753 Filed on March 10, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$713.0K	$1.319M	$250.0K
YoY Change	185.2%	206.74%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.332M	$21.73M	$4.560M
YoY Change	38.86%	93.14%
% of Gross Profit
Research & Development	$22.46M	$80.33M	$16.47M
YoY Change	36.39%	39.18%
% of Gross Profit
Depreciation & Amortization	$810.0K	$3.200M	$570.0K
YoY Change	42.11%	146.15%	42.5%
% of Gross Profit
Operating Expenses	$28.80M	$102.1M	$21.03M
YoY Change	36.92%	47.99%
Operating Profit		-$100.7M
YoY Change		46.99%
Interest Expense	-$426.0K	$1.906M	-$320.0K
YoY Change	33.13%	94.69%
% of Operating Profit
Other Income/Expense, Net	$598.0K	-$586.0K	$560.0K
YoY Change	6.79%	117.84%
Pretax Income	-$29.14M	-$101.3M	-$20.76M
YoY Change	40.38%	47.27%
Income Tax
% Of Pretax Income
Net Earnings	-$29.14M	-$101.3M	-$20.76M
YoY Change	40.38%	47.24%
Net Earnings / Revenue	-4087.38%	-7680.06%	-8304.0%
Basic Earnings Per Share		-$2.73
Diluted Earnings Per Share	-$766.0K	-$2.73	-$1.797M
COMMON SHARES
Basic Shares Outstanding	37.09M shares	37.17M shares	35.81M
Diluted Shares Outstanding		37.17M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$154.3M	$154.3M	$185.8M
YoY Change	-16.95%	-16.96%	1140.04%
Cash & Equivalents	$101.1M	$101.1M	$92.80M
Short-Term Investments	$53.15M	$53.15M	$92.98M
Other Short-Term Assets	$5.273M	$5.273M	$4.900M
YoY Change	7.61%	7.61%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$459.6M	$459.6M	$190.7M
YoY Change	141.0%	140.99%	1029.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$56.08M	$56.08M	$19.53M
YoY Change	187.17%	-9.99%	627.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.400M	$4.133M	$842.0K
YoY Change	185.04%	58.96%	7554.55%
Total Long-Term Assets	$60.21M	$60.21M	$64.91M
YoY Change	-7.23%	-7.22%	1089.43%
TOTAL ASSETS
Total Short-Term Assets	$459.6M	$459.6M	$190.7M
Total Long-Term Assets	$60.21M	$60.21M	$64.91M
Total Assets	$519.8M	$519.8M	$255.6M
YoY Change	103.36%	103.35%	1044.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.819M	$3.819M	$3.680M
YoY Change	3.78%	3.22%	7.01%
Accrued Expenses	$9.562M	$16.18M	$9.161M
YoY Change	4.38%	24.44%	147.53%
Deferred Revenue	$28.32M		$2.024M
YoY Change	1299.06%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$48.69M	$48.69M	$18.85M
YoY Change	158.37%	159.0%	48.96%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$19.65M
YoY Change	-100.0%	-100.0%	79.32%
Other Long-Term Liabilities	$143.0K	$374.2M	$0.00
YoY Change		427.8%
Total Long-Term Liabilities	$143.0K	$374.2M	$19.65M
YoY Change	-99.27%	313.04%	79.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$48.69M	$48.69M	$18.85M
Total Long-Term Liabilities	$143.0K	$374.2M	$19.65M
Total Liabilities	$422.9M	$422.9M	$109.4M
YoY Change	286.54%	286.57%	359.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$264.3M		-$162.9M
YoY Change	62.18%		73.09%
Common Stock	$4.000K		$4.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$96.87M	$96.87M	$146.2M
YoY Change
Total Liabilities & Shareholders Equity	$519.8M	$519.8M	$255.6M
YoY Change	103.36%	103.35%	1044.01%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$29.14M	-$101.3M	-$20.76M
YoY Change	40.38%	47.24%
Depreciation, Depletion And Amortization	$810.0K	$3.200M	$570.0K
YoY Change	42.11%	146.15%	42.5%
Cash From Operating Activities	$11.88M	-$50.25M	-$10.66M
YoY Change	-211.46%	60.61%	-58.16%
INVESTING ACTIVITIES
Capital Expenditures	-$80.00K	$3.313M	-$7.490M
YoY Change	-98.93%	-79.53%	4061.11%
Acquisitions
YoY Change
Other Investing Activities	$9.753M	$39.49M	-$92.73M
YoY Change	-110.52%	-142.58%
Cash From Investing Activities	$9.673M	$36.17M	-$100.2M
YoY Change	-109.65%	-133.21%	58852.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	21.74M	$22.42M	128.5M
YoY Change	-83.08%	-89.69%	1387.38%
NET CHANGE
Cash From Operating Activities	11.88M	-$50.25M	-10.66M
Cash From Investing Activities	9.673M	$36.17M	-100.2M
Cash From Financing Activities	21.74M	$22.42M	128.5M
Net Change In Cash	43.29M	$8.341M	17.63M
YoY Change	145.58%	-89.21%	-203.64%
FREE CASH FLOW
Cash From Operating Activities	$11.88M	-$50.25M	-$10.66M
Capital Expenditures	-$80.00K	$3.313M	-$7.490M
Free Cash Flow	$11.96M	-$53.56M	-$3.170M
YoY Change	-477.35%	12.84%	-87.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001822462
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-39634
CY2021	dei	Entity Registrant Name EntityRegistrantName	Foghorn Therapeutics Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5271393
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	500 Technology Square, Ste 700
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2021	dei	City Area Code CityAreaCode	617
CY2021	dei	Local Phone Number LocalPhoneNumber	586-3100
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 Par Value
CY2021	dei	Trading Symbol TradingSymbol	FHTX
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	208800000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41421964	shares
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	92975000	USD
CY2021	dei	Auditor Firm AuditorFirmId	34
CY2021	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	101136000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92795000	USD
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	53153000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	300000000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5273000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4917000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	459562000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	190687000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	17563000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	19528000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1733000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3819000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1733000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2400000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	842000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38516000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42804000	USD
CY2021Q4	us-gaap	Assets Assets	519774000	USD
CY2020Q4	us-gaap	Assets Assets	255594000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3680000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9562000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9161000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6994000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3981000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	28317000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2024000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48692000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18846000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19654000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51338000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	58361000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	322730000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12546000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	143000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2021Q4	us-gaap	Liabilities Liabilities	422903000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	109407000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41299720	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41299720	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36790946	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36790946	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	361133000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	309126000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-264256000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-162936000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	96871000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	146187000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	519774000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	255594000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1319000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	430000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80325000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57715000	USD
CY2020	us-gaap	Interest Expense InterestExpense	979000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21728000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11246000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	102053000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	68961000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-100734000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-68531000	USD
CY2021	us-gaap	Interest Expense InterestExpense	1906000	USD
CY2021	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	2553000	USD
CY2020	fhtx	Interest Income And Other Income Expense InterestIncomeAndOtherIncomeExpense	1001000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	69000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1233000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-222000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-586000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-269000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-101320000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-68800000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.73
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.73
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.23
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.23
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37171147	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37171147	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11046802	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11046802	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-101320000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-68800000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-7000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-101323000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68807000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-68800000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-88016000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	176405000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	114000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1221000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	188000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2961000	USD
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-7000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	146187000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1418000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8384000	USD
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-3000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-101320000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	96871000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-101320000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-68800000	USD
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	8384000	USD
CY2020	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2961000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3227000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1327000	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	206000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1233000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-222000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	69000	USD
CY2021	fhtx	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	4288000	USD
CY2020	fhtx	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	4201000	USD
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	318000	USD
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	238000	USD
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-179000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1814000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3194000	USD
CY2021	fhtx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-4010000	USD
CY2020	fhtx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	15135000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4670000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	300000000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	135000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	474000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2653000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	336477000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	14570000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50250000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31286000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3313000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16183000	USD
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	250000	USD
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	99984000	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	92981000	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	139470000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	36173000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-108914000	USD
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	42205000	USD
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	122121000	USD
CY2021	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	89861000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1418000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1221000	USD
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	19800000	USD
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	21205000	USD
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	15530000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22418000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	217473000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	8341000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	77273000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94528000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17255000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102869000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94528000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1716000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	660000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	295000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2400000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	101136000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92795000	USD
CY2021Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	1733000	USD
CY2020Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	1733000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102869000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94528000	USD
CY2020Q3	fhtx	Proceeds From Upfront Payment ProceedsFromUpfrontPayment	15000000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-101300000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-68800000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-264300000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition and the accrual of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></div>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk and of significant suppliers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. As of December 31, 2021, the Company maintained cash, cash equivalents and marketable securities at financial institutions in excess of federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies, and expects to continue to rely, on a small number of vendors to provide services, supplies and materials for certain activities related to its programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.</span></div>
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021Q4	fhtx	Number Of Collaborative Agreements NumberOfCollaborativeAgreements	2	agreement
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5938954	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5034905	shares
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	53163000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	53153000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	92982000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	92975000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	184742000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	22893000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	21631000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	5330000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	2103000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	17563000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	19528000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3200000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1300000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5596000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3513000	USD
CY2021Q4	fhtx	Accrued Tenant Improvements AccruedTenantImprovements	13000	USD
CY2020Q4	fhtx	Accrued Tenant Improvements AccruedTenantImprovements	2385000	USD
CY2021Q4	fhtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	3079000	USD
CY2020Q4	fhtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	2146000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	495000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	979000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	379000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	138000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9562000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9161000	USD
CY2021Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1200000	USD
CY2021	us-gaap	Long Term Debt Weighted Average Interest Rate Over Time LongTermDebtWeightedAverageInterestRateOverTime	0.095
CY2020	us-gaap	Long Term Debt Weighted Average Interest Rate Over Time LongTermDebtWeightedAverageInterestRateOverTime	0.064
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	76941000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.007
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.004
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.788
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.785
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5016460	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.93
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	46882000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1719563	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.41
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	508774	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.79
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	306740	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.22
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5920509	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.88
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	88720000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5920509	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	7.88
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	88720000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2435439	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.62
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5300000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3500000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.40
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.01
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	4800000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	8384000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2961000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	20800000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	300000000	USD
CY2021	fhtx	Proceeds From Upfront Payment ProceedsFromUpfrontPayment	15000000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.058
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.064
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.044
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.037
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.008
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.304
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.316
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	61083000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39289000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9367000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4955000	USD
CY2021Q4	fhtx	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	157000	USD
CY2020Q4	fhtx	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	174000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	5300000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1010000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1403000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	436000	USD
CY2021Q4	fhtx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	15952000	USD
CY2020Q4	fhtx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	17032000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	93262000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	62896000	USD
CY2021Q4	fhtx	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	3551000	USD
CY2020Q4	fhtx	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	2819000	USD
CY2021Q4	fhtx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	10566000	USD
CY2020Q4	fhtx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	11694000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14117000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14513000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	79145000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	48383000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	30800000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	21800000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	7547000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	7032000	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	61000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	2892000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	1217000	USD
CY2021	us-gaap	Lease Cost LeaseCost	10439000	USD
CY2020	us-gaap	Lease Cost LeaseCost	8310000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	9737000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	3086000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	38306000	USD
CY2021	fhtx	Change In Operating Lease Liability Right Of Use Asset Re Measurement ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement	0	USD
CY2020	fhtx	Change In Operating Lease Liability Right Of Use Asset Re Measurement ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement	7384000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y8M12D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0535
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6994000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0535
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9954000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10051000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10378000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10626000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10881000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	19705000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	71595000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11802000	USD
CY2021Q4	fhtx	Lessee Operating Lease Liability Estimated Lease Incentives LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives	1461000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	58332000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	62342000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3981000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51338000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	58361000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	58332000	USD
CY2021Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	1900000	USD
CY2021	us-gaap	Sublease Income SubleaseIncome	2500000	USD
CY2020	us-gaap	Sublease Income SubleaseIncome	1000000	USD

Files In Submission

Name	View Source	Status
0001628280-22-005753-index-headers.html	Edgar Link	pending
0001628280-22-005753-index.html	Edgar Link	pending
0001628280-22-005753.txt	Edgar Link	pending
0001628280-22-005753-xbrl.zip	Edgar Link	pending
ex1021-foghornxloxocollabo.htm	Edgar Link	pending
ex1022-aremploymentagreeme.htm	Edgar Link	pending
ex1023-employmentagreement.htm	Edgar Link	pending
ex1024-employmentagreement.htm	Edgar Link	pending
ex1025-employmentagreement.htm	Edgar Link	pending
ex1026-transitionagreement.htm	Edgar Link	pending
ex1027-emplnoncomp.htm	Edgar Link	pending
ex23130503foghornconsent-2.htm	Edgar Link	pending
fhtx-20211231.htm	Edgar Link	pending
fhtx-20211231.xsd	Edgar Link	pending
fhtx-20211231xex311.htm	Edgar Link	pending
fhtx-20211231xex312.htm	Edgar Link	pending
fhtx-20211231xex321.htm	Edgar Link	pending
fhtx-20211231xex322.htm	Edgar Link	pending
fhtx-20211231_cal.xml	Edgar Link	unprocessable
fhtx-20211231_def.xml	Edgar Link	unprocessable
fhtx-20211231_g1.jpg	Edgar Link	pending
fhtx-20211231_g10.jpg	Edgar Link	pending
fhtx-20211231_g11.jpg	Edgar Link	pending
fhtx-20211231_g12.jpg	Edgar Link	pending
fhtx-20211231_g13.jpg	Edgar Link	pending
fhtx-20211231_g14.jpg	Edgar Link	pending
fhtx-20211231_g15.jpg	Edgar Link	pending
fhtx-20211231_g16.jpg	Edgar Link	pending
fhtx-20211231_g17.jpg	Edgar Link	pending
fhtx-20211231_g18.jpg	Edgar Link	pending
fhtx-20211231_g19.jpg	Edgar Link	pending
fhtx-20211231_g2.jpg	Edgar Link	pending
fhtx-20211231_g20.jpg	Edgar Link	pending
fhtx-20211231_g21.jpg	Edgar Link	pending
fhtx-20211231_g22.jpg	Edgar Link	pending
fhtx-20211231_g23.jpg	Edgar Link	pending
fhtx-20211231_g24.jpg	Edgar Link	pending
fhtx-20211231_g25.jpg	Edgar Link	pending
fhtx-20211231_g26.jpg	Edgar Link	pending
fhtx-20211231_g27.jpg	Edgar Link	pending
fhtx-20211231_g28.jpg	Edgar Link	pending
fhtx-20211231_g29.jpg	Edgar Link	pending
fhtx-20211231_g3.jpg	Edgar Link	pending
fhtx-20211231_g30.jpg	Edgar Link	pending
fhtx-20211231_g31.jpg	Edgar Link	pending
fhtx-20211231_g32.jpg	Edgar Link	pending
fhtx-20211231_g33.jpg	Edgar Link	pending
fhtx-20211231_g34.jpg	Edgar Link	pending
fhtx-20211231_g35.jpg	Edgar Link	pending
fhtx-20211231_g36.jpg	Edgar Link	pending
fhtx-20211231_g37.jpg	Edgar Link	pending
fhtx-20211231_g4.jpg	Edgar Link	pending
fhtx-20211231_g5.jpg	Edgar Link	pending
fhtx-20211231_g6.jpg	Edgar Link	pending
fhtx-20211231_g7.jpg	Edgar Link	pending
fhtx-20211231_g8.jpg	Edgar Link	pending
fhtx-20211231_g9.jpg	Edgar Link	pending
fhtx-20211231_htm.xml	Edgar Link	completed
fhtx-20211231_lab.xml	Edgar Link	unprocessable
fhtx-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
image_0b.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FHTX
Foghorn Therapeutics Inc. Stock $fhtx

2021 Q4 Form 10-K Financial Statement

#000162828022005753 Filed on March 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FHTX Foghorn Therapeutics Inc. Stock $fhtx

2021 Q4 Form 10-K Financial Statement

#000162828022005753 Filed on March 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FHTX
Foghorn Therapeutics Inc. Stock $fhtx